Systematic literature review
Accelerate evidence generation from scientific literature
Built on provider-native terminology, IMO Health advances screening, extraction, and interpretation – delivering faster, trusted insights and measurable ROI.
Completing one literature review can take up to
months.
IMO Health’s SLR solution reduces that time to hours with the same level of scientific rigor and transparency.
Define or import precise criteria with ease
Customize specific inclusion and exclusion criteria to support reproducibility and even the most complex research methodologies – no coding needed.
Automate knowledge discovery across sources
Leverage AI to search thousands of PubMed abstracts and authorized proprietary sources, extracting defined data points and eliminating duplicate work.
Accelerate evidence synthesis
Quickly generate structured, ready-to-use exports for evidence tables, supporting decision-making, publication creation, and HTA submissions.
Ensure transparency and reproducibility
With an explainable, human-in-the-loop approach, every decision is clear, traceable, and adjustable – so you stay in control.
Leverage a customizable, LLM-agnostic platform that quickly scales systematic review with confidence.
FAQS
Still have questions? Let's get them answered.
Click to explore our literature review FAQs or contact us if you don’t see yours. We’re happy to help.
How does IMO Health use artificial intelligence (AI) to optimize article screening and data extraction?
What is the human-in-the-loop AI approach?
Is IMO Health's solution customizable for my organization's specific needs?
Yes. IMO Precision Literature Review is configurable to your preferred review methodology, therapeutic focus, and output requirements. It’s scalable across teams, with flexible integrations and governance that fit seamlessly into existing workflows.
How can IMO Health solutions maximize ROI for life sciences organizations?
By reducing review timelines from months to hours, IMO Precision Literature Review accelerates study design, regulatory submissions, and market access activities. Faster evidence generation lowers costs, reduces false starts, and enables earlier, more confident decision-making.